| scholarly article | Q13442814 |
| P50 | author | Thomas G Beach | Q67218653 |
| P2093 | author name string | Geidy Serrano | |
| Douglas G Walker | |||
| Lih-Fen Lue | |||
| Lucia I Sue | |||
| Christopher T Schmitz | |||
| P2860 | cites work | TREM-2 (triggering receptor expressed on myeloid cells 2) is a phagocytic receptor for bacteria | Q37124881 |
| Variants in triggering receptor expressed on myeloid cells 2 are associated with both behavioral variant frontotemporal lobar degeneration and Alzheimer's disease | Q37316511 | ||
| Cross-regulation of signaling by ITAM-associated receptors | Q37366524 | ||
| Nasu-Hakola disease: The first case reported by Nasu and review: The 50th Anniversary of Japanese Society of Neuropathology | Q37760572 | ||
| Microglial activatory (immunoreceptor tyrosine-based activation motif)- and inhibitory (immunoreceptor tyrosine-based inhibition motif)-signaling receptors for recognition of the neuronal glycocalyx. | Q38012092 | ||
| Structure, expression pattern and biological activity of molecular complex TREM-2/DAP12. | Q38086376 | ||
| Heterozygous TREM2 mutations in frontotemporal dementia | Q38442725 | ||
| TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis | Q38978510 | ||
| The surface-exposed chaperone, Hsp60, is an agonist of the microglial TREM2 receptor | Q39849114 | ||
| Triggering receptor expressed in myeloid cells 2 (TREM2) trafficking in microglial cells: continuous shuttling to and from the plasma membrane regulated by cell stimulation. | Q40283765 | ||
| Distribution and signaling of TREM2/DAP12, the receptor system mutated in human polycystic lipomembraneous osteodysplasia with sclerosing leukoencephalopathy dementia | Q40490966 | ||
| Developmental regulation of TREM2 and DAP12 expression in the murine CNS: implications for Nasu-Hakola disease | Q41845995 | ||
| Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. | Q42057034 | ||
| Sequential proteolytic processing of the triggering receptor expressed on myeloid cells-2 (TREM2) protein by ectodomain shedding and γ-secretase-dependent intramembranous cleavage | Q42244965 | ||
| A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia | Q42726693 | ||
| Developmental neuronal death in hippocampus requires the microglial CD11b integrin and DAP12 immunoreceptor | Q44207850 | ||
| Blockade of TREM-2 exacerbates experimental autoimmune encephalomyelitis | Q48218333 | ||
| Diagnostic criteria for neuropathologic assessment of Alzheimer's disease | Q48662480 | ||
| Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia | Q48939108 | ||
| Dap12 and Trem2, molecules involved in innate immunity and neurodegeneration, are co-expressed in the CNS. | Q52058734 | ||
| Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. | Q53348339 | ||
| Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease | Q73789480 | ||
| TREM2 Variants in Alzheimer's Disease | Q22250873 | ||
| Variant of TREM2 Associated with the Risk of Alzheimer's Disease | Q22250874 | ||
| Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes | Q22254042 | ||
| A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells | Q24291798 | ||
| Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype | Q24611595 | ||
| Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation | Q24644706 | ||
| TREM2 and the neuroimmunology of Alzheimer's disease | Q28304401 | ||
| GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease | Q29417137 | ||
| The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease | Q29614948 | ||
| TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis | Q33281667 | ||
| TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice | Q33343490 | ||
| Nasu-Hakola syndrome: polycystic lipomembranous osteodysplasia with sclerosing leucoencephalopathy and presenile dementia | Q33679427 | ||
| Altered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2. | Q33727947 | ||
| Indirect inhibition of Toll-like receptor and type I interferon responses by ITAM-coupled receptors and integrins. | Q33822008 | ||
| TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis | Q33864853 | ||
| Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. | Q33908939 | ||
| Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer's disease | Q33999537 | ||
| Microglia: a sensor to threats in the nervous system? | Q34405840 | ||
| Secretory PLA2-IIA: a new inflammatory factor for Alzheimer's disease | Q35094556 | ||
| TREMs in the immune system and beyond | Q35140795 | ||
| Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies | Q35593764 | ||
| The expanding roles of ITAM adapters FcRgamma and DAP12 in myeloid cells. | Q35640941 | ||
| Nasu-Hakola disease (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy--PLOSL): a dementia associated with bone cystic lesions. From clinical to genetic and molecular aspects | Q35720396 | ||
| The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2. | Q36121607 | ||
| Microglia and the control of autoreactive T cell responses | Q36499416 | ||
| Essential role of the microglial triggering receptor expressed on myeloid cells-2 (TREM2) for central nervous tissue immune homeostasis | Q36713607 | ||
| The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007 | Q36805238 | ||
| The immunoreceptor tyrosine-based activation motif (ITAM) -related factors are increased in synovial tissue and vasculature of rheumatoid arthritic joints | Q36907683 | ||
| TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease | Q36952445 | ||
| The TREM-1/DAP12 pathway | Q37055878 | ||
| Heterogeneous expression of the triggering receptor expressed on myeloid cells-2 on adult murine microglia | Q37088528 | ||
| P433 | issue | 4 | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| neurodegeneration | Q1755122 | ||
| P304 | page(s) | 469-480 | |
| P577 | publication date | 2014-11-11 | |
| P1433 | published in | Brain Pathology | Q4955776 |
| P1476 | title | TREM2 Protein Expression Changes Correlate with Alzheimer's Disease Neurodegenerative Pathologies in Post-Mortem Temporal Cortices | |
| P478 | volume | 25 |
| Q39112446 | A candidate regulatory variant at the TREM gene cluster associates with decreased Alzheimer's disease risk and increased TREML1 and TREM2 brain gene expression |
| Q92455137 | Alzheimer's Disease Research Using Human Microglia |
| Q52644596 | Alzheimer's Disease, Oligomers, and Inflammation. |
| Q39251035 | Applying fluid biomarkers to Alzheimer's disease |
| Q38658658 | Central nervous system myeloid cells as drug targets: current status and translational challenges |
| Q36846582 | Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease |
| Q57168893 | Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup |
| Q48372341 | Changes in the expression of genes related to neuroinflammation over the course of sporadic Alzheimer's disease progression: CX3CL1, TREM2, and PPARγ. |
| Q39015642 | Contributions of triggering-receptor-expressed-on-myeloid-cells-2 to neurological diseases |
| Q40544443 | Convergent Genetic and Expression Datasets Highlight TREM2 in Parkinson's Disease Susceptibility |
| Q54113689 | Could Alzheimer's Disease Originate in the Periphery and If So How So? |
| Q54942608 | Current Concepts of Neurodegenerative Mechanisms in Alzheimer's Disease. |
| Q35555134 | Different mechanisms of apolipoprotein E isoform-dependent modulation of prostaglandin E2 production and triggering receptor expressed on myeloid cells 2 (TREM2) expression after innate immune activation of microglia |
| Q38902345 | Divergent Neuroinflammatory Regulation of Microglial TREM Expression and Involvement of NF-κB. |
| Q91812826 | Dynamic changes of CSF sTREM2 in preclinical Alzheimer's disease: the CABLE study |
| Q60912714 | Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology |
| Q38752410 | Exosomes from NSC-34 Cells Transfected with hSOD1-G93A Are Enriched in miR-124 and Drive Alterations in Microglia Phenotype. |
| Q36204253 | Expression and processing analyses of wild type and p.R47H TREM2 variant in Alzheimer's disease brains |
| Q47722340 | Fluid biomarkers for microglial activation and axonal injury in multiple sclerosis |
| Q47737214 | Higher Peripheral TREM2 mRNA Levels Relate to Cognitive Deficits and Hippocampal Atrophy in Alzheimer's Disease and Amnestic Mild Cognitive Impairment. |
| Q35857978 | Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay |
| Q26796857 | Immune phenotypes of microglia in human neurodegenerative disease: challenges to detecting microglial polarization in human brains |
| Q36454535 | Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease |
| Q47920956 | Markers of microglia in post-mortem brain samples from patients with Alzheimer's disease: a systematic review |
| Q53392184 | Microglia in Alzheimer's disease. |
| Q60949648 | Microglia in Neurological Diseases: A Road Map to Brain-Disease Dependent-Inflammatory Response |
| Q91786444 | Microglia in neurodegeneration |
| Q92150715 | Microglial Phenotyping in Neurodegenerative Disease Brains: Identification of Reactive Microglia with an Antibody to Variant of CD105/Endoglin |
| Q54946040 | Molecular biomarkers of Alzheimer's disease: progress and prospects. |
| Q48235737 | Neocortical and hippocampal TREM2 protein levels during the progression of Alzheimer's disease. |
| Q38430889 | Neuroimaging Feature Terminology: A Controlled Terminology for the Annotation of Brain Imaging Features |
| Q90263563 | Neuroinflammatory Processes, A1 Astrocyte Activation and Protein Aggregation in the Retina of Alzheimer's Disease Patients, Possible Biomarkers for Early Diagnosis |
| Q58130251 | New genetic players in late-onset Alzheimer's disease: Findings of genome-wide association studies |
| Q92854080 | Patterns of Expression of Purinergic Receptor P2RY12, a Putative Marker for Non-Activated Microglia, in Aged and Alzheimer's Disease Brains |
| Q42712047 | Pharmacological Tools to Activate Microglia and their Possible use to Study Neural Network Patho-physiology. |
| Q48525796 | TREM2 Ameliorates Neuronal Tau Pathology Through Suppression of Microglial Inflammatory Response |
| Q42736886 | TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy |
| Q48029728 | TREM2 expression in the human brain: a marker of monocyte recruitment? |
| Q38646212 | TREM2 in Neurodegenerative Diseases |
| Q35762212 | TREM2 mRNA Expression in Leukocytes Is Increased in Alzheimer's Disease and Schizophrenia |
| Q36765735 | TREM2 upregulation correlates with 5-hydroxymethycytosine enrichment in Alzheimer's disease hippocampus |
| Q90429690 | TREM2-Dependent Effects on Microglia in Alzheimer's Disease |
| Q38711499 | The Alzheimer's disease risk factors apolipoprotein E and TREM2 are linked in a receptor signaling pathway |
| Q36161131 | The TREM2-DAP12 signaling pathway in Nasu-Hakola disease: a molecular genetics perspective |
| Q89287765 | The Transcriptional Regulatory Properties of Amyloid Beta 1-42 may Include Regulation of Genes Related to Neurodegeneration |
| Q92799298 | Therapeutic Effect of Modulating TREM-1 via Anti-inflammation and Autophagy in Parkinson's Disease |
| Q57418361 | Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease? |
| Q48163749 | Variable expression of microglial DAP12 and TREM2 genes in Nasu-Hakola disease. |
Search more.